Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

943 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).
Herold M, Schulze A, Niederwieser D, Franke A, Fricke HJ, Richter P, Freund M, Ismer B, Dachselt K, Boewer C, Schirmer V, Weniger J, Pasold R, Winkelmann C, Klinkenstein C, Schulze M, Arzberger H, Bremer K, Hahnfeld S, Schwarzer A, Müller C, Müller C; East German Study Group Hematology and Oncology (OSHO). Herold M, et al. Among authors: freund m. J Cancer Res Clin Oncol. 2006 Feb;132(2):105-12. doi: 10.1007/s00432-005-0023-2. Epub 2005 Aug 9. J Cancer Res Clin Oncol. 2006. PMID: 16088404 Clinical Trial.
Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO).
Pönisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, Dachselt K, Richter P, Schirmer V, Schulze A, Subert R, Harksel B, Grobe N, Stelzer E, Schulze M, Bittrich A, Freund M, Pasold R, Friedrich T, Helbig W, Niederwieser D; East German Study Group of Hematology and Oncology (OSHO). Pönisch W, et al. Among authors: freund m. J Cancer Res Clin Oncol. 2006 Apr;132(4):205-12. doi: 10.1007/s00432-005-0074-4. Epub 2006 Jan 10. J Cancer Res Clin Oncol. 2006. PMID: 16402269 Clinical Trial.
Chemotherapy for mobilisation of Ph-negative progenitor cells from patients with CML: impact of different mobilisation regimens.
Deininger M, Pönisch W, Krahl R, Leiblein S, Edel E, Lange T, Fiedler F, Freund M, Franke A, Pasold R, von Grünhagen U, Herold M, Dölken G, Hoffmann FA, Uhle R, Schultze W, Steglich J, Schwarzer A, Richter P, Winkelmann C, Kettner E, Dachselt K, Subert R, Schwalbe E, Doepper J, Helbig W, Niederwieser D; East German Study Group Haematology/Oncology (OSHO). Deininger M, et al. Among authors: freund m. Bone Marrow Transplant. 2001 Jun;27(11):1125-32. doi: 10.1038/sj.bmt.1703057. Bone Marrow Transplant. 2001. PMID: 11551022 Clinical Trial.
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group.
Hallek M, Schmitt B, Wilhelm M, Busch R, Kröber A, Fostitsch HP, Sezer O, Herold M, Knauf W, Wendtner CM, Kuse R, Freund M, Franke A, Schriever F, Nerl C, Döhner H, Thiel E, Hiddemann W, Brittinger G, Emmerich B; German Chronic Lymphocytic Leukaemia Study Group. Hallek M, et al. Among authors: freund m. Br J Haematol. 2001 Aug;114(2):342-8. doi: 10.1046/j.1365-2141.2001.02959.x. Br J Haematol. 2001. PMID: 11529853 Free article. Clinical Trial.
Treatment of relapsed or refractory adult acute lymphocytic leukemia.
Freund M, Diedrich H, Ganser A, Gramatzki M, Heil G, Heyll A, Henke M, Hiddemann W, Haas R, Kuse R, et al. Freund M, et al. Cancer. 1992 Feb 1;69(3):709-16. doi: 10.1002/1097-0142(19920201)69:3<709::aid-cncr2820690318>3.0.co;2-g. Cancer. 1992. PMID: 1730121
943 results